Article
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
26 May 2022
Abstract excerpt
In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR) dependence leads to clinically aggressive tumors with few therapeutic options. We used ATAC-seq (assay for transposase-accessible chromatin sequencing), RNA-seq, and DNA sequencing to investigate 22 organoids, six patient-derived xenografts, and 12 cell lines. We identified the well-characterized AR-dependent and neuroendocrine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
